title: Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
authors.affiliation: Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome , Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Adriano
authors.initials: A
authors.lastname: Salaroli
authors.forename: Alessandra
authors.initials: A
authors.lastname: Serrao
authors.forename: Irene
authors.initials: I
authors.lastname: Zacheo
authors.forename: Roberta
authors.initials: R
authors.lastname: Saracino
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D015897:Comorbidity; D006801:Humans; D000068877:Imatinib Mesylate; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000453:epidemiology; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate